Search in:

ClinicoEconomics and Outcomes Research Volume 9, 2017 - Issue

Submit an article Journal homepage

Open access

100

Views

CrossRef citations to date

Altmetric

Original Research

Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK

Michele R Wilson1 RTI Health Solutions, Research Triangle Park, NC, USACorrespondence[email protected]

Ismail Azzabi Zouraq2 Takeda Pharmaceuticals International AG, Zurich, Switzerland

Helene Chevrou-Severac2 Takeda Pharmaceuticals International AG, Zurich, Switzerland

Ross Selby3 Takeda UK Ltd., Bucks, UK

Matthew C Kerrigan4 PHMR Limited, London, UK

Pages 641-652 | Published online: 16 Oct 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (12)

Elisabetta Fenu, Vasily Lukyanov, Annabel Acs, Xenia Radu, Stephanie Stypa, Aren Fischer, John K. Marshall & Mark Oppe. (2022) Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada. PharmacoEconomics - Open 6:4, pages 519-537.
Crossref

Brad D. Constant, Edwin F. de Zoeten, Marisa G. Stahl, Ravy K. Vajravelu, James D. Lewis, Blair Fennimore, Mark E. Gerich & Frank I. Scott. (2022) Delays Related to Prior Authorization in Inflammatory Bowel Disease. Pediatrics 149:3.
Crossref

Bob G SchultzIbrahim DiakiteJohn A CarterSonya J SnedecorRobin Turpin. (2021) Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis. Journal of Managed Care & Specialty Pharmacy 27:11, pages 1592-1600.
Crossref

Ting Zhou, Yanan Sheng, Haijing Guan, Rui Meng & Zijing Wang. (2021) Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China. Frontiers in Public Health 9.
Crossref

Seth R. ShafferElbert HuangShivani PatelDavid T. Rubin. (2021) Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. American Journal of Gastroenterology 116:1, pages 125-133.
Crossref

Luis Hernandez, Hiroyo Kuwabara, Anshul Shah, Kaoru Yamabe, Heather Burnett, Kyle Fahrbach, Maria Koufopoulou & Ryuichi Iwakiri. (2019) Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. PharmacoEconomics 38:1, pages 69-84.
Crossref

Frank I Scott, David T Rubin, Subra Kugathasan, Athos Bousvaros, Charles O Elson, Rodney D Newberry, Gil Y Melmed, Joel Pekow, James W Fleshman, Brendan M Boyle, Uma Mahadevan, Lisa Marie Cannon, Millie D Long, Raymond K Cross, Christina Y Ha, Karen L Lasch, Anne M Robinson, Janice F Rafferty, Jessica J Lee, Karen D Cowden Dahl, Alandra Weaver, Nataly Shtraizent, Gerard Honig, Andrés Hurtado-Lorenzo & Caren A Heller. (2019) Challenges in IBD Research: Pragmatic Clinical Research. Inflammatory Bowel Diseases 25:Supplement_2, pages S40-S47.
Crossref

Ferdinando D’Amico, Gionata Fiorino, Laurent Peyrin-Biroulet & Silvio Danese. (2019) Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. Immunotherapy 11:7, pages 565-575.
Crossref

Cristina Trigo-Vicente, Vicente Gimeno-Ballester, Santiago García-López & Alejandro López-Del Val. (2018) Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis. International Journal of Clinical Pharmacy 40:6, pages 1411-1419.
Crossref

Bin Wu, Zhenhua Wang & Qiang Zhang. (2018) Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis. Inflammatory Bowel Diseases 24:11, pages 2291-2302.
Crossref

Pieter Hindryckx & Gregor Novak. (2018) Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?. Best Practice & Research Clinical Gastroenterology 32-33, pages 9-15.
Crossref

. (2017) Vedolizumab a cost-effective option in UC in the UK. PharmacoEconomics & Outcomes News 790:1, pages 34-34.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK

Articles from other publishers (12)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK

Citations (12)

Articles from other publishers (12)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date